Mario A. Eisenberger, William G. Nelson; How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Wor
No takes yet. Share an insight, caveat, or question.
Eisenberger et al. (1996) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: